DPP4 Protein (CD26 Protein)

Dipeptidyl Peptidase IV (Cluster of Differentiation 26)

 DPP4 / CD26 Products

DPP4 / CD26 Protein, Recombinant

Molecule	Species	Description	Cat. No
DPP4/CD26	Human	DPP4/CD26/Fc Protein, Recombinant	10688-H01H
DPP4/CD26	Human	DPP4/CD26 Protein, Recombinant	10688-HNCH

  10688-HNCH:  The specific activity is > 6,000 pmoles / min / µg. Measured by its ability to cleave the fluorogenic peptide substrate, Gly-Pro-7-amido-4-methylcoumarin (GP-AMC).

DPP4 / CD26 cDNA Clone

Molecule	Species	Description	Cat. No
DPP4/CD26	Human	Homo sapiens DPP4/CD26 cDNA Clone(NM_001935.3)	HG10688-M
DPP4/CD26	Mouse	Mouse CD26/DPP4 cDNA Clone / ORF Clone	MG50718-G

DPP4 / CD26 Related Areas

Cancer>>Angiogenesis>>Other Proteases & Related Molecules in Angiogenesis>>DPP4/CD26

Enzyme>>Protease & Regulator>>Serine Protease & Regulator>>DPPIV Family>>DPP4/CD26

Immunology>>Adaptive Immunity>>Costimulation & Costimulatory Molecule>>DPP4/CD26

Immunology>>Cluster of Differentiation>>B Cell CD Antigen>>DPP4/CD26

Immunology>>Cluster of Differentiation>>Monocyte/Macrophage CD Antigen>>Macrophage Markers>>DPP4/CD26

Immunology>>Cluster of Differentiation>>Natural Killer (NK) Cell CD Antigen>>DPP4/CD26

Immunology>>Cluster of Differentiation>>T Cell CD Antigen>>Other>>DPP4/CD26

DPP4 / CD26 Alternative Names

DPP4, CD26, DPPIV, ADABP, ADCP2, TP103

DPP4 / CD26 Background

Dipeptidyl peptidase-4 (DPP4) or adenosine deaminase complexing protein 2 (ADCP 2) or T-cell activation antigen CD26 is a serine exopeptidase belonging to the S9B protein family that cleaves X-proline dipeptides from the N-terminus of polypeptides, such as chemokines, neuropeptides, and peptide hormones. The enzyme is a type II transmembrane glycoprotein, expressed on the surface of many cell types. It is also present in serum and other body fluids in a truncated form (sCD26/DPPIV). The soluble CD26 (sCD26) as a tumour marker for the detection of colorectal cancer (CRC) and advanced adenomas. As both a regulatory enzyme and a signalling factor, DPP4 has been evaluated and described in many studies. DPP4 inhibition results in increased blood concentration of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This causes an increase in glucose-dependent stimulation of insulin secretion, resulting in a lowering of blood glucose levels. Recent studies have shown that DPP4 inhibitors can induce a significant reduction in glycosylated haemoglobin (HbA(1c)) levels, either as monotherapy or as a combination with other antidiabetic agents. Research has also demonstrated that DPP4 inhibitors portray a very low risk of hypoglycaemia development, and are a new pharmacological class of drugs for treating Type 2 diabetes.

DPP4 / CD26 Related Studies

1. Doupis J, et al. (2008) DPP4 inhibitors: a new approach in diabetes treatment. Adv Ther. 25(7): 627-43.
2. Havre PA, et al. (2008) The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci. 13: 1634-45.
3. De Chiara L, et al. (2009) Soluble CD26 levels and its association to epidemiologic parameters in a sample population. Dis Markers. 7(6): 311-6.
4. Matteucci E, et al. (2009) Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Curr Med Chem. 16(23): 2943-51.